Page last updated: 2024-12-09
5-iodouridine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
5-iodouridine: RN given refers to unlabeled cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 1268108 |
| CHEMBL ID | 3249838 |
| SCHEMBL ID | 97335 |
| MeSH ID | M0109914 |
Synonyms (30)
| Synonym |
|---|
| 5-iodouridine |
| uridine, 5-iodo- |
| 1024-99-3 |
| nsc-523375 |
| 5-iodouridine, 95% |
| A800578 |
| 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-iodo-pyrimidine-2,4-dione;nsc 523375; ac1l5tpi |
| 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione |
| 1-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-iodopyrimidine-2,4(1h,3h)-dione |
| unii-yzk4kvc76p |
| nsc 523375 |
| yzk4kvc76p , |
| einecs 213-833-1 |
| AKOS015896912 |
| 2,4-dihydroxy-5-iodo-1-beta-d-ribofuranosylpyrimidine |
| CHEMBL3249838 |
| 1-[3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-iodopyrimidine-2,4(1h,3h)-dione |
| SCHEMBL97335 |
| AC-32308 |
| c9h11in2o6 |
| mfcd00006532 |
| 5-iodouridine, >=97.0% (hplc) |
| DS-10692 |
| 1-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-iodopyrimidine-2,4(1h,3h)-dione |
| 1-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-5-iodo-1,2,3,4-tetrahydropyrimidine-2,4-dione |
| AMY40627 |
| EN300-221745 |
| 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodo-1,2,3,4-tetrahydropyrimidine-2,4-dione |
| F12678 |
| Z2197277787 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (3)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1135723 | Growth inhibition of human MGL8 cells at 5 uM after 48 hrs | 1978 | Journal of medicinal chemistry, Jul, Volume: 21, Issue:7 | Synthesis of branched-chain apiosylpyrimidines and their inhibition of lymphocyte proliferation. |
| AID1135725 | Growth inhibition of human MGL8 cells at 500 uM after 48 hrs relative to control | 1978 | Journal of medicinal chemistry, Jul, Volume: 21, Issue:7 | Synthesis of branched-chain apiosylpyrimidines and their inhibition of lymphocyte proliferation. |
| AID1135724 | Growth inhibition of human MGL8 cells at 50 uM after 48 hrs relative to control | 1978 | Journal of medicinal chemistry, Jul, Volume: 21, Issue:7 | Synthesis of branched-chain apiosylpyrimidines and their inhibition of lymphocyte proliferation. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (14)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (28.57) | 18.7374 |
| 1990's | 3 (21.43) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 21.67
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.67) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||